

# DoD Healthcare Management System Modernization (DHMSM®)



DoD Healthcare Management System Modernization (DHMSM) consists primarily of MHS GENESIS, which is the DoD's electronic health record system that is now fully fielded to all major medical treatment facilities. In FY23, the Joint Interoperability Test Command (JITC) executed a DOT&E-approved operational test on the billing component of the MHS GENESIS system, known as Revenue Cycle Expansion (RevX), that was added after the initial deployment of the system. DOT&E will publish a report on this test event in FY25.

DHMSM® and MHS GENESIS® are registered trademarks of the DHMSM Program Management Office (PMO).

## SYSTEM DESCRIPTION

---

MHS GENESIS is a modernized electronic health records system for the DoD, the Department of Veterans Affairs, the U.S. Coast Guard, and the National Oceanic and Atmospheric Administration. It creates a single healthcare record for each patient that can be utilized by all four organizations.

MHS GENESIS comprises three major elements: (1) the Millennium suite of applications, which provides medical capabilities; (2) Dentrix Enterprise, which provides dental capabilities; and (3) the Orion Rhapsody Integration Engine, which enables the majority of the external information exchanges.

The RevX component of MHS GENESIS covers all revenue features, to include patient scheduling, registration, preauthorization, medical coding, claims submission, billing, and payment processing.

## MISSION

---

DoD and other Federal Government medical staff use MHS GENESIS to manage delivery of healthcare within garrison facilities. DoD medical staff also use MHS GENESIS to perform administrative support, front desk operations, logistics, billing, and business intelligence.

## PROGRAM

---

MHS GENESIS is a Business System Category I program that completed fielding to all major medical treatment facilities in March 2024. With deployment completed, MHS GENESIS is approaching the capability support phase of its acquisition pathway.

DOT&E approved the TEMP in October 2017. The program completed IOT&E in July 2018, with multiple rounds of FOT&E and cyber testing between 2019 and 2023. The DHMSM PMO has committed to executing at least one additional FOT&E event to capture any outstanding requirements and capabilities that have not been assessed. The PMO continues to fund the execution of Persistent Cyber Operations (PCO) to help maintain and improve cyber survivability.

The DHMSM PMO began deploying the Revenue Cycle Expansion (RevX) component of MHS GENESIS as part of its regular fielding activities for new waves of MHS GENESIS in September 2022. The PMO completed fielding to sites where MHS GENESIS had previously been fielded without RevX in April 2023. RevX covers all revenue features, to include patient scheduling, registration, preauthorization, medical coding, claims submission, billing, and payment processing. It introduces new capabilities and workflows to support patient accounting and billing.

## » MAJOR CONTRACTORS

---

- Leidos Partnership for Defense Health – Reston, Virginia
- Oracle Health – Austin, Texas (Millennium suite)
- Henry Schein ONE – American Fork, Utah (Dentrix Enterprise)

## TEST ADEQUACY

---

JITC executed a DOT&E-approved operational test of the RevX component of MHS GENESIS in May 2023. DOT&E observed the test and will report the findings in 2QFY25. This is a delay from the FY23 Annual Report. DOT&E expects to report separately on PCO activities covering FY24 in FY25.

## PERFORMANCE

---

### » EFFECTIVENESS AND SUITABILITY

---

DOT&E will report on the operational effectiveness and suitability of the RevX capability in 2QFY25.

### » SURVIVABILITY

---

The RevX OT&E did not evaluate cyber survivability because RevX is a subcomponent of MHS GENESIS, and its survivability cannot be evaluated separately.

## RECOMMENDATIONS

---

The DHMSM PMO should:

1. Conduct an FOT&E of MHS GENESIS to re-evaluate the operational effectiveness and suitability of MHS GENESIS, including RevX, with patient-facing components and at OCONUS sites.
2. Continue to fund and execute PCO on MHS GENESIS and its components.

The Director, Defense Health Agency (DHA) should:

1. Continue to fund and execute PCO on DHA infrastructure and platforms that support and integrate with MHS GENESIS.